All Oncology News

Paolo Tarantino MD, and V. K. Gadi, MD, PhD discuss data from DESTINY-Breast03 and DESTINY-Breast06.

Adrienne G. Waks, MD, parses out recent and upcoming data in HER2+ breast cancer and discusses why abbreviated neoadjuvant regimens are not ready for primetime.

Sonya Reid, MD, MPH, discusses barriers to universal germline testing utilization in breast cancer, particularly among underserved populations.

Sarah Sammons, MD, discusses the evolving treatment landscape for metastatic HER2-postive breast cancer.

Circulating tumor DNA is in constant flux, rendering its evaluation potentially useful in metastatic breast cancer management.

V. Craig Jordan, PhD, of The University of Texas MD Anderson Cancer Center and a pioneer in the field of breast cancer, died on June 9, 2024.

Justin M. Watts, MD, discusses 5-year efficacy and safety data for olutasidenib in IDH1-mutant, relapsed/refractory AML.

Pembrolizumab plus ibrutinib or idelalisib produced responses in patients with Richter transformation of chronic lymphocytic leukemia.

The FDA has granted fast track designation to HP518 for androgen receptor–positive triple-negative breast cancer.

The FDA has expanded the orphan drug designation for SurVaxM, a brain cancer immunotherapy developed at Roswell Park Comprehensive Cancer Center.

Kassem Faraj, MD, details the 340B Drug Pricing program and data from a study examining participation in the program for patients with advanced prostate cancer.

Brian Rini, MD, details recent data in renal cell carcinoma surrounding the utility of KIM-1 as a potential biomarker and next steps for KIM-1 research.

Sara M. Tolaney, MD, MPH, discusses the use of HER2-directed therapy in the curative setting for HER2-positive breast cancer.

Roswell Park Comprehensive Cancer Center has promoted 3 nurses to leadership roles and new leaders were named in Case Management and Patient Education.

Hope Rugo, MD, discusses the management of treatment-limiting toxicities in breast cancer, including the use of antibody-drug conjugates and immunotherapy.

Tanios S. Bekaii-Saab, MD, FACP, details data from the ESOPEC trial in early-stage gastroesophageal cancers, and findings from Checkmate-9DW in HCC.

J. Ryan Mark, MD, FACS, is joining Fox Chase Cancer Center as an associate professor in the Department of Urology and the Fox Chase – Temple Urologic Institute.

The marketing authorization application seeking the approval of vimseltinib for the treatment of tenosynovial giant cell tumor is under EMA review.

The type II variation application for frontline nivolumab plus ipilimumab in unresectable/advanced hepatocellular carcinoma was validated by the EMA.

The EMA has accepted a marketing authorization application seeking approval of belantamab mafodotin regimens in relapsed/refractory multiple myeloma.

C. Ola Landgren, MD, PhD, highlights how therapeutic improvements with quadruplet regimens will benefit all patients with newly diagnosed multiple myeloma.

Rezatapopt has displayed early signals of efficacy and tolerability in p53 Y220C-mutated solid tumors.

Richard Kim, MD, discusses the standard treatment approaches and unmet needs for patients with resectable colorectal cancer.

Razane El Hajj Chehade, MD, discusses a retrospective study of risk factors for irAEs in patients with metastatic renal cell carcinoma.

A phase 1b trial is evaluating the TIL therapy TBio-4101 plus pembrolizumab in PD-(L)1 inhibitor–resistant head and neck squamous cell carcinoma.

C. Ola Landgren, MD, PhD, discusses the use of quadruplet regimens in patients with newly diagnosed multiple myeloma.

The FDA completed an end-of-phase 2 meeting for botensilimab plus balstilimab in relapsed/refractory microsatellite stable colorectal cancer.

The National Medical Products Administration accepted for review the supplemental new drug application for toripalimab plus bevacizumab in advanced HCC.

The addition of nivolumab to tivozanib did not improve PFS in advanced metastatic renal cell carcinoma following prior immune checkpoint inhibition

A UCSF-led study alerts transwomen and physicians to interpret standard screening guidelines with caution.